12,372 trials
Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment — -21.57; -5.58 percent change — p=<0.001
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — -1.02; -0.14 Percent — p=<.001
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 — -0.76; 0.16 Percentage of glycosylated hemoglobin — p=<.001
Moderate to Severe Glabellar Frown Lines
Primary: Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's…
Moderate to Severe Glabellar Frown Lines
Primary: Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's…
Leukopenia
Primary: Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period — 4; 11 participants
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Intraocular Pressure (IOP) Change From Baseline at All 9 Time Points During the Study (0800, 1000 and 1600 Hrs at Weeks 2, 6, and 12) — -7.1; -6.8; -6.8; -6.1 mmHg
Epilepsy
Primary: Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) During the Treatment Period (up to 5.5 Years) — 311 Subjects
Tobacco Dependence
Primary: 7-day Point Prevalence Smoking Abstinence at End of Treatment (Week 8) — 7; 5; 7 participants — p=0.615
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) in the ITT (Non-squamous) Population — 376; 379 days — p=0.401
Major Depression · Multiple Sclerosis · Amyotrophic Lateral Sclerosis
Primary: Hamilton Depression Scale (HAM-D 17). — 15 depression severity — p=0.01
Nausea and Vomiting of Pregnancy
Primary: Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall…
Hepatitis · Hepatitis B, Chronic · Cirrhosis
Primary: Number of Participants With Clinical Response — 65; 62; 85; 82 Participants
Type 2 Diabetes Mellitus
Primary: Number of Participants With Adverse Events. — 14; 11; 143; 146 participants
Influenza
Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25